TY - JOUR
T1 - Respiratory care in familial dysautonomia
T2 - Systematic review and expert consensus recommendations
AU - Kazachkov, Mikhail
AU - Palma, Jose Alberto
AU - Norcliffe-Kaufmann, Lucy
AU - Bar-Aluma, Bat El
AU - Spalink, Christy L.
AU - Barnes, Erin P.
AU - Amoroso, Nancy E.
AU - Balou, Stamatela M.
AU - Bess, Shay
AU - Chopra, Arun
AU - Condos, Rany
AU - Efrati, Ori
AU - Fitzgerald, Kathryn
AU - Fridman, David
AU - Goldenberg, Ronald M.
AU - Goldhaber, Ayelet
AU - Kaufman, David A.
AU - Kothare, Sanjeev V.
AU - Levine, Jeremiah
AU - Levy, Joseph
AU - Lubinsky, Anthony S.
AU - Maayan, Channa
AU - Moy, Libia C.
AU - Rivera, Pedro J.
AU - Rodriguez, Alcibiades J.
AU - Sokol, Gil
AU - Sloane, Mark F.
AU - Tan, Tina
AU - Kaufmann, Horacio
N1 - Publisher Copyright:
© 2018
PY - 2018/8
Y1 - 2018/8
N2 - Background: Familial dysautonomia (Riley-Day syndrome, hereditary sensory autonomic neuropathy type-III) is a rare genetic disease caused by impaired development of sensory and afferent autonomic nerves. As a consequence, patients develop neurogenic dysphagia with frequent aspiration, chronic lung disease, and chemoreflex failure leading to severe sleep disordered breathing. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of respiratory disorders in familial dysautonomia. Methods: We performed a systematic review to summarize the evidence related to our questions. When evidence was not sufficient, we used data from the New York University Familial Dysautonomia Patient Registry, a database containing ongoing prospective comprehensive clinical data from 670 cases. The evidence was summarized and discussed by a multidisciplinary panel of experts. Evidence-based and expert recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. Results: Recommendations were formulated for or against specific diagnostic tests and clinical interventions. Diagnostic tests reviewed included radiological evaluation, dysphagia evaluation, gastroesophageal evaluation, bronchoscopy and bronchoalveolar lavage, pulmonary function tests, laryngoscopy and polysomnography. Clinical interventions and therapies reviewed included prevention and management of aspiration, airway mucus clearance and chest physical therapy, viral respiratory infections, precautions during high altitude or air-flight travel, non-invasive ventilation during sleep, antibiotic therapy, steroid therapy, oxygen therapy, gastrostomy tube placement, Nissen fundoplication surgery, scoliosis surgery, tracheostomy and lung lobectomy. Conclusions: Expert recommendations for the diagnosis and management of respiratory disease in patients with familial dysautonomia are provided. Frequent reassessment and updating will be needed.
AB - Background: Familial dysautonomia (Riley-Day syndrome, hereditary sensory autonomic neuropathy type-III) is a rare genetic disease caused by impaired development of sensory and afferent autonomic nerves. As a consequence, patients develop neurogenic dysphagia with frequent aspiration, chronic lung disease, and chemoreflex failure leading to severe sleep disordered breathing. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of respiratory disorders in familial dysautonomia. Methods: We performed a systematic review to summarize the evidence related to our questions. When evidence was not sufficient, we used data from the New York University Familial Dysautonomia Patient Registry, a database containing ongoing prospective comprehensive clinical data from 670 cases. The evidence was summarized and discussed by a multidisciplinary panel of experts. Evidence-based and expert recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. Results: Recommendations were formulated for or against specific diagnostic tests and clinical interventions. Diagnostic tests reviewed included radiological evaluation, dysphagia evaluation, gastroesophageal evaluation, bronchoscopy and bronchoalveolar lavage, pulmonary function tests, laryngoscopy and polysomnography. Clinical interventions and therapies reviewed included prevention and management of aspiration, airway mucus clearance and chest physical therapy, viral respiratory infections, precautions during high altitude or air-flight travel, non-invasive ventilation during sleep, antibiotic therapy, steroid therapy, oxygen therapy, gastrostomy tube placement, Nissen fundoplication surgery, scoliosis surgery, tracheostomy and lung lobectomy. Conclusions: Expert recommendations for the diagnosis and management of respiratory disease in patients with familial dysautonomia are provided. Frequent reassessment and updating will be needed.
KW - Aspiration pneumonia
KW - Chemoreflex failure
KW - Neurogenic dysphagia
KW - Non-cystic fibrosis bronchiectasis
KW - Rare neurological disorders
UR - http://www.scopus.com/inward/record.url?scp=85048943784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048943784&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2018.06.017
DO - 10.1016/j.rmed.2018.06.017
M3 - Review article
C2 - 30053970
AN - SCOPUS:85048943784
SN - 0954-6111
VL - 141
SP - 37
EP - 46
JO - Respiratory Medicine
JF - Respiratory Medicine
ER -